



# **ACLS 2006 REVIEW PACKET**


This packet is intended for review only. Textbooks are available for purchase.

### **RCPALS**

720 N. Valley, Suite F Anaheim, CA 92801 Phone #: (714) 808-9036 (714) 808-9030 Fax: (714) 844-4935 Email: rcpals@hotmail.com Website: http://www.rcpals.com







#### ACLS 2006 ALGORITHMS Chest discomfort suggestive of ischemia 2 EMS assessment and care and hospital preparation: . Monitor, support ABCs. Be prepared to provide CPR and defibrillation · Administer oxygen, aspirin, nitroglycerin, and morphine if needed . If available, obtain 12-lead ECG; if ST-elevation: Notify receiving hospital with transmission or interpretation Begin fibrinolytic checklist (Figure 2) Notified hospital should mobilize hospital resources to respond to STEMI Immediate ED assessment (<10 min) Immediate ED general treatment · Check vital signs; evaluate oxygen saturation Start oxygen at 4 L/min; maintain 0, sat >90% · Establish IV access Aspirin 160 to 325 mg (if not given by EMS) · Obtain/review 12-lead ECG · Nitroglycerin sublingual, spray, or IV · Perform brief, targeted history, physical exam . Morphine IV if pain not relieved by nitroglycerin · Review/complete fibrinolytic checklist (Figure 2); check contraindications (Table 1) Obtain initial cardiac marker levels, initial electrolyte and coagulation studies Obtain portable chest x-ray (<30 min) Review initial 12-lead ECG 5 13 ST elevation or new or ST depression or dynamic Normal or nondiagnostic changes presumably new LBBB; T-wave inversion; strongly in ST segment or T wave strongly suspicious for injury suspicious for ischemia Intermediate/Low-Risk UA ST-Elevation MI (STEMI) High-Risk Unstable Angina/ Non-ST-Elevation MI (UA/NSTEMI) 10 Develops high or intermedi-Start adjunctive treatments as Start adjunctive treatments as Yes ate risk criteria (Tables 3, 4) indicated (see text for contraindications) indicated (see text for contraindications) Do not delay reperfusion Nitroglycerin troponin-positive? β-Adrenergic receptor blockers β-Adrenergic receptor blockers Clopidogrel Clopidogrel · Heparin (UFH or LMWH) Heparin (UFH or LMWH) No 15 Glycoprotein IIb/IIIa inhibitor Consider admission to 7 11 ED chest pain unit or to monitored bed in ED Time from onset of >12 hours Admit to monitored bed Follow: symptoms ≤12 hours? Assess risk status (Tables 3, 4) · Serial cardiac markers (including troponin) Repeat ECG/continuous ≤12 hours ST segment monitoring High-risk patient (Tables 3, 4 for 8 Consider stress test risk stratification): Reperfusion strategy: · Refractory ischemic chest pain Therapy defined by patient and center · Recurrent/persistent ST deviation criteria (Table 2) Ventricular tachycardia · Be aware of reperfusion goals: Hemodynamic instability Develops high or intermedi-Door-to-balloon inflation (PCI) Signs of pump failure Yes ate risk criteria (Tables 3, 4) goal of 90 min · Early invasive strategy, including OR - Door-to-needle (fibrinolysis) catheterization and revascularization troponin-positive? goal of 30 min for shock within 48 hours of an AMI · Continue adjunctive therapies and: Continue ASA, heparin, and other - ACE inhibitors/angiotensin therapies as indicated. 17 No receptor blocker (ARB) within ACE inhibitor/ARB 24 hours of symptom onset HMG CoA reductase inhibitor If no evidence of ischemia - HMG CoA reductase inhibitor (statin therapy) or infarction, can discharge (statin therapy) with follow-up Not at high risk: cardiology to risk-stratify

### **ACLS 2006 ALGORITHMS**

	CHEST PAIN CHECKLIST FOR STEMI FIBRINOLYTI	C THERAPY	
Step One:	Has patient experienced chest discomfort for greater than 15 minutes and less than 12 hours?		
	YES		
1	Does ECG show STEMI or new or presumably new LBBB?		
	YES	¥ 10	
Step Two:	Are there contraindications to fibrinolysis?  If ANY of the following is CHECKED YES, fibrinolysis MAY be contraindicated.		
Systolic BP greater than 180 mm Hg		O YES	NO
Diastolic BP greater than 110 mm Hg		O YES	NO
Right vs. left arm systolic BP difference greater than 15 mm Hg		O YES	NO
History of structural central nervous system disease		O YES	NO
Significant closed head/facial trauma within the previous 3 months		O YES	NO
Recent (within 6 wks) major trauma, surgery (including laser eye surgery), GI/GU bleed		O YES	NO
Bleeding or clotting problem or on blood thinners		O YES	NO
CPR greater than 10 minutes		O YES	NO
Pregnant female		O YES	NO
Serious systemic disease (eg, advanced/terminal cancer, severe liver or kidney disease)		O YES	NO
Step Three:	Is patient at high risk?  If ANY of the following is CHECKED YES, CONSIDER Transport	Transfer to PCI Facility	
Heart rate greater than or equal to 100 bpm AND systolic BP less than 100 mm Hg			NO
Pulmonary edema (rales)		O YES	NO
Signs of shock (cool, clammy)		O YES	NO
Contraindications to fibrinolytic therapy		YES	NO

#### ACLS 2006 ALGORITHMS

## TABLE 1. Fibrinolytic Therapy: Contraindications and Cautions for Fibrinolytic Use in STEMI From ACC/AHA 2004 Guideline Update\*

#### **Absolute Contraindications**

- · Any prior intracranial hemorrhage
- Known structural cerebral vascular lesion (eg, AVM)
- Known malignant intracranial neoplasm (primary or metastatic)
- Ischemic stroke within 3 months EXCEPT acute ischemic stroke within 3 hours
- · Suspected aortic dissection
- · Active bleeding or bleeding diathesis (excluding menses)
- · Significant closed head trauma or facial trauma within 3 months

#### Relative Contraindications

- · History of chronic, severe, poorly controlled hypertension
- Severe uncontrolled hypertension on presentation (SBP >180 mm Hg or DBP >110 mm Hg)
- History of prior ischemic stroke >3 months, dementia, or known intracranial pathology not covered in contraindications
  - Traumatic or prolonged (>10 minutes) CPR or major surgery (<3 weeks)
  - · Recent (within 2 to 4 weeks) internal bleeding
  - · Noncompressible vascular punctures
  - For streptokinase/anistreplase: prior exposure (>5 days ago) or prior allergic reaction to these agents
  - · Pregnancy
  - · Active peptic ulcer
  - · Current use of anticoagulants: the higher the INR, the higher the risk of bleeding

AVM indicates arteriovenous malformation; SBP, systolic blood pressure; DBP, diastolic blood pressure; and INR, International Normalized Ratio.

\*Viewed as advisory for clinical decision making and may not be all-inclusive or definitive.

†Could be an absolute contraindication in low-risk patients with myocardial infarction.

#### **ACLS 2006 ALGORITHMS**

### TABLE 2. ST-Segment Elevation or New or Presumably New LBBB: Evaluation for Reperfusion

Step 1: Assess time and risk

Time since onset of symptoms

Risk of STEMI

Risk of fibrinolysis

Time required to transport to skilled PCI catheterization suite

Step 2: Select reperfusion (fibrinolysis or invasive) strategy

*Note:* If presentation <3 hours and no delay for PCI, then no preference for either strategy.

### Fibrinolysis is generally preferred if:

- Early presentation (≤3 hours from symptom onset)
- Invasive strategy is not an option (eg, lack of access to skilled PCI facility or difficult vascular access) or would be delayed
  - -Medical contact-to-balloon or door-balloon >90 min
  - -(Door-to-balloon) minus (door-to-needle) is >1 hour
  - · No contraindications to fibrinolysis

## An invasive strategy is generally preferred if:

- Late presentation (symptom onset >3 hours ago)
- Skilled PCI facility available with surgical backup
- Medical contact-to-balloon or doorballoon <90 min</li>
- (Door-to-balloon) minus (door-toneedle) is <1 hour</li>
- Contraindications to fibrinolysis, including increased risk of bleeding and ICH
- High risk from STEMI (CHF, Killip class is ≥3)
  - · Diagnosis of STEMI is in doubt

Modified from ACC/AHA 2004 Update Recommendations. 112

